Risk factors and diagnostic biomarkers for asymptomatic immune checkpoint inhibitor-related myocarditis in patients with esophageal cancer after immunotherapy

Figure 1 Tumor biomarker levels. A: Cancer antigen 125; B: Carcinoembryonic antigen; C: Squamous cell carcinoma antigen. ^aP > 0.05. CA125: Cancer antigen 125; CEA: Carcinoembryonic antigen; SCC: Squamous cell carcinoma antigen.

Figure 2 Echocardiography. A: Initial left ventricular ejection fraction; B: Left ventricular end-diastolic diameter; C: Left ventricular end-systolic diameter; D: Stroke volume. ^aP > 0.05. LVEF: Left ventricular ejection fraction; LVEDD: Left ventricular end-diastolic diameter; LVESD: Left ventricular end-systolic diameter; SV: Stroke volume.

Figure 3 Diagnostic value of various indicators for myocarditis associated with asymptomatic immune checkpoint. A: Age (years); B: Gender; C: Creatine kinase (U/L); D: Creatine kinase-MB (g/L). AUC: Area under the receiver operating characteristic curve.

Figure 4 Joint predictive model for asymptomatic immune checkpoint inhibitor-associated myocarditis. ROC: Receiver operating characteristic; AUC: Area under the receiver operating characteristic curve.